A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was 'in patients undergoing a surgery for endocarditis is a biological valve or mechanical valve superior for achieving long-term low rates of reinfection?' Altogether more than 41 papers were found using the reported search, of which nine represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Out of the studies that include statistical comparisons, in mechanical valve replacement the average endocarditis recurrence rate ranged from approximately 3 to 9% and in biological valves from approximately 7 to 29%. Out of the studies that specifically compared the outcomes of the two valves, 50% concluded there to be no significant difference when separated from other risk factors and 50% recommended a mechanical valve for lower recurrence and higher survival rates. The Euro Heart Survey found that 63% of valve replacements were mechanical, due to young age (90%) and physician preference (75%) and only 21% bioprosthetic. Current guidelines from American College of Cardiology/American Heart Association (ACC/AHA) recommend a mechanical valve in patients -65 years old and a bioprosthetic valve if )65, without risk factors for thromboembolism, but this is based on class II evidence (conflicting evidence or opinion). These guidelines are not specific to patients with infective endocarditis, so it is vital to review the literature related to this. Three of the studies in the search specify that for patients under 60-65 years old, a mechanical valve has greater benefit, but this was not found to be true for the over 65 years. It can be concluded that for patients under 65 years old, a mechanical valve may offer greater freedom from reoperation and increased long-term survival when compared to a bioprosthetic valve (assuming no other co-morbidities), although this divide is narrowing with the use of newer generation bioprosthetic valves and has to be off-set against potential bleeding risks. For patients over 65 years, other important variants need to be considered including patient choice, correct protocols of antibiotics and radical debridement.
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS w1x.
Three-part question
In wpatients undergoing a surgery for endocarditisx is wa biological valvex or wmechanical valvex superior wfor achieving long-term low rates of reinfectionx?
Clinical scenario
You are an a multi-disciplinary team (MDT) meeting discussing the case of a young patient with infective endocarditis and a senior consultant states that a biological valve must be inserted to reduce the risk of reinfection, even though the patient will require a mechanical valve replace-*Corresponding author. 57A St Stephens Avenue, London, W12 8JA, UK. Tel.yfax: q44-208-740-7318.
E-mail address: sophielnewton@gmail.com (S. Newton). ment in the future when the biological valve wears out. You resolve to check the latest evidence yourself on rates of reinfection between mechanical and prosthetic valve replacements in endocarditis to help determine which would be best for this patient.
Search strategy
Medline 1950-August 2009 using OVID interface wendocarditis.mp or exp endocarditisyx AND wexp biopros-thesisyOR bioprosthesis.mpx AND wmechanical valve.mp OR mechanical prosthesis.mpx.
Limit to English language AND full text. All reference lists of relevant papers were also checked for additional papers.
Search outcome
Forty-one papers were found using the reported search. From these nine papers were identified that provided the best evidence to answer the question. These are presented in Table 1 .
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Results
Sweeney et al. w2x reviewed 185 patients who had undergone valve replacement for active bacterial endocarditis, 88 had a bioprosthetic valve and 97 a mechanical valve. There was a significant reduction in recurrent infection leading to reoperation in the mechanical valve group, compared to bioprosthetic (3.3% vs. 7.4%, P-0.01). The actuarial rate of freedom from reoperation was also higher for mechanical at four years (94.6% vs. 75% bioprosthetic, P-0.01), as was four-year actuarial survival rate (87.4% mechanical vs. 78.7% bioprosthetic, P-0.05).
Wos et al. w3x found similar results when reviewing 71 patients with valve replacements following endocarditis. There was a statistical difference in the recurrence rate of endocarditis, with higher rates in the patients with bioprosthetic valves, compared to the patients with mechanical valves (28.6% vs. 8.5%, Ps0.028), with concurrent higher rates of reoperation (21% vs. 4.2%, Ps0.022). Fedoruk et al. w9x found that unadjusted survival rates at 20 years were greater for patients with mechanical valves (56.5"8.1% vs. 26.4"4.9% for bioprosthetic valves, Ps0.007), but overall they concluded that prosthesis type was not an independent predictor of reoperation. The key independent predictors of outcome were age, intravenous (IV) drug useyhuman immunodeficiency virus (HIV) and surgical technique.
Similarly, Renzulli et al. w7x found that the choice of valve substitute used in patients with infective endocarditis did not affect recurrence rate of infection. Instead, the multivariate analysis demonstrated that prosthetic endocarditis (Ps0.00001), positive valvular cultures (Ps0.0039), and persistence of postoperative fever (Ps0.000001) were independent risk factors for recurrence of endocarditis.
Edwards et al. w4x investigated determinants of reoperation for prosthetic valvular endocarditis (PVE) and found that age was the only significant independent predictor in outcome (specifically in 30-day mortality, Ps0.04), with no evidence to suggest that one type of prosthesis was superior in determining survival or freedom from reoperation. Moon et al. w6x investigated further into the effects of age in valvular replacement following endocarditis and found survival was independent of type of prosthesis used (P)0.27). The different rates of linearised reinfection or residual endocarditis after five years between mechanical and bioprosthetic were insignificant among the collective group (P)0.25). There was also no difference in medium and long-term survival with mechanical or bioprosthetic valves (four-year survival 82"6% vs. 79"3% and 20 years 46"10% vs. 41"6%, P)0.50). Among those patients under 60 years old with a biological valve, the long-term freedom from reoperation was low (51"5% at 10 years, 19"6% at 15 years), therefore leading to the conclusion that mechanical valves are most suitable for young patients with endocarditis. In the older age group ()60 years old), however, there were similar results with freedom from reoperation at 15 years with both bioprosthetic and mechanical valves (84"7% vs. 74"9%). Nguyen et al. w10x concluded that a bioprosthetic valve replacement for infective endocarditis is associated with a lower five-year survival than the use of a mechanical valve in patients )65 years old wadjusted hazard ratio (HR) 4.14, Ps0.018x, but no such statistical significant relationship was observed in patients )65 years old. Hammermeister et al. w5x explained similar findings as due to a greater rate of primary valve failure with bioprosthetic valves compared to mechanical valves in patients -65 years old, but not in those aged G65 years.
None of the papers are randomised controlled trails (RCTs), but more importantly despite attempts to adjust for differences in the patient populations in many of the papers, the groups of endocarditis patients receiving biological and mechanical valves are often quite different. Young patients receiving biological valves may more often be current IV drug abusers, or the patients may have incompletely treated endocarditis and both of these factors may in themselves cause an increased rate of infection whatever type of valve is used.
Clinical bottom line
Out of the studies that include statistical comparisons, in mechanical valve replacement the average endocarditis recurrence rate ranged from approximately 3 to 9% and in biological valves from approximately 7 to 29%. Out of the studies that specifically compared the outcomes of the two valves, 50% concluded there to be no significant difference when separated from other risk factors and 50% recommended a mechanical valve for lower recurrence and higher survival rates. It is worth noting that the older studies compare mechanical valves to first-generation bioprosth-Best Evidence Topic Downloaded from https://academic.oup.com/icvts/article-abstract/11/6/784/831000 by guest on 23 December 2018 etic valves, such as Ionescu-Shiley pericardial valves, which were removed from the market due to clinical failure and replaced with improved second-generation bioprosthetic valves.
Three of the studies in the search specify that for patients under 60-65 years old, a mechanical valve has greater benefit, but this was not found to be true for the over 65 years. It can be concluded that for patients under 65 years old, a mechanical valve may offer greater freedom from reoperation and increased long-term survival when compared to a bioprosthetic valve (assuming no other comorbidities), although this divide is narrowing with the use of newer generation bioprosthetic valves and has to be offset against potential bleeding risks. For patients over 65 years, other important variants need to be considered including patient choice, correct protocols of antibiotics and radical debridement.
